Scientists reveal how common anti-inflammatory drugs boost immunotherapy cancer treatments
Widely-used anti-inflammatory drugs make tumours more responsive to treatments which boost the anti-cancer function of the immune system, according to early University of Manchester research funded by Cancer Research UK.
The proof-of-concept study on the combination of immunotherapy with anti-inflammatory drugs – used to manage pain and reduce inflammation in diseases like arthritis – was carried out by a team led by Dr Santiago Zelenay at the Cancer Research UK Manchester Institute (CRUK MI), part of The University of Manchester, and published in the journal Cancer Discovery, a journal of the American Association for Cancer Research, on the 25/05/21.
According to the study, immunotherapy works better and faster in mice when given in combination with anti-inflammatory drugs, that target a protein called COX-2, which helps cancer cells escape the immune system and grow aggressively.
Although this is early research, these findings may have important implications for improving the treatment of lung, intestinal, and breast cancers, among others, which often make a lot of the COX-2 protein.
The researchers aimed to identify why some tumours are more responsive to immune checkpoint inhibitors than others – a major open question for scientists. When the researchers treated tumours growing in mice using an immune checkpoint inhibitor, a type of immunotherapy commonly used to treat cancer, less than 30% of the mice responded to treatment, a rate similar to that seen in some cancer types in human patients.
But when the mice were given the immune checkpoint inhibitors along with a common non-steroidal anti-inflammatory called celecoxib, which targets COX-2 and reduces prostaglandin E2 production, up to 70% of the mice responded to the combined treatment.
These findings inform ongoing and future clinical trials including in Manchester at the Christie NHS Foundation Trust to determine if, and in which cases, these combinations might work best in patients so it’s important to stress that we are not suggesting patients should self-medicate with any of these drugs.
Dr Santiago Zelenay
Lead Researcher and Group Leader, Cancer Inflammation and Immunity Group, CRUK MI
Similar results were achieved when combining immune checkpoint inhibitors with steroids – a surprising finding as steroids are widely considered to suppress the immune system. These results were supported by analysing fragments from patient tumours, where treatment with anti-inflammatory drugs produced the same changes as those seen in mice. The novel approach was conducted in collaboration with the teams of Dr Daniela Thommen and Professor Ton Schumacher from the Netherlands Cancer Institute in Amsterdam.
“These proof-of-concept results are exciting,” said lead researcher Dr Santiago Zelenay, from The University of Manchester and Cancer Research UK Manchester Institute. “Our work supports evidence that widely used anti-inflammatory drugs, commonly used to treat conditions like arthritis, can favour a type of inflammatory response that boosts the cancer-restraining function of our immune system.”
“These findings inform ongoing and future clinical trials including in Manchester at the Christie NHS Foundation Trust to determine if, and in which cases, these combinations might work best in patients so it’s important to stress that we are not suggesting patients should self-medicate with any of these drugs.”
Immune checkpoint inhibitors block proteins called checkpoints that are made by some types of immune cells, such as T cells. The checkpoints normally stop immune responses from being too strong – which contributes to autoimmune diseases – but tumours can use them to protect themselves from the immune system.
Dr Zelenay said: “Improving the efficacy of the immune checkpoint blockade remains a major clinical need, so our progress in this area is very exciting.
“Our study has identified mechanisms by which anti-inflammatory drugs can rapidly enhance an immune response in tumours that can prevent their growth.”
Michelle Mitchell, chief executive of Cancer Research UK, said: “Checkpoint inhibitors are widely used in the treatment of melanoma and lung cancer to name a few, but they don’t work for everyone. Making them more effective would make a huge difference to many, so finding ways to unleash their potential is vital.
“Although this is early research, funding in this area is important because it can set the course for practice-changing clinical trials later down the line. Repurposing drugs that have already passed safety tests is a great opportunity to save more lives with tools already at our disposal.”